# **Ujjivan Small Finance Bank**



### Seasonal/election-related stress reflects in 1Q; still delivers healthy RoA Your success is our success

BFSI - Banks > Result Update > July 26, 2024

**TARGET PRICE (Rs): 60** 

Ujjivan SFB posted a 4% miss on earnings—PAT at Rs3bn/RoA at 2.9%—mainly due to lower other income and rising LLP. Ujjivan SFB's AUM growth too moderated, to 19% YoY/1% QoQ in Q1FY25, due to a conscious decision to slacken disbursements (amid election-induced disruption) and owing to regulatory caution slowing down growth in certain geographies. Ujjivan had indicated asset-quality disruption in 1Q during its recent analyst meet which manifested with 29bps QoQ jump in GNPA ratio. It expects some normalization at start-2Q as the election-related impact is now behind, but guides to elevated credit cost in FY25E, factoring in rising stress in MFI/some contingent provision buildup. We cut FY25E-27E earnings by 3-4% as we build-in slightly slower growth/higher LLP; we also trim our target multiple to 1.4x Jun-26E ABV, causing a cut in TP to Rs60/sh (from Rs65). We, though, retain BUY on Ujjivan, which we still prefer in the SFB space, given its superior return ratios (RoA: >2.5%/RoE: ~20-21%) and potential transition into a 'Universal Bank'.

Ujjivan Small Finance Bank: Financial Snapshot (Standalone)								
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E			
Net profit	10,999	12,815	12,781	14,222	16,683			
Loan growth (%)	30.6	26.3	20.1	22.9	22.7			
NII growth (%)	52.1	26.4	16.9	19.8	21.3			
NIM (%)	9.8	9.6	9.3	9.1	9.0			
PPOP growth (%)	133.1	29.1	15.9	22.7	23.9			
Adj. EPS (Rs)	6.0	6.6	6.6	7.4	8.6			
Adj. EPS growth (%)	0.0	10.4	0.3	11.3	17.3			
Adj. BV (INR)	20.5	28.8	34.0	39.7	46.6			
Adj. BVPS growth (%)	39.5	41.7	18.7	17.3	17.6			
RoA (%)	3.9	3.5	2.9	2.6	2.5			
RoE (%)	33.3	26.6	20.8	19.6	19.6			
P/E (x)	7.4	6.7	6.6	6.0	5.1			
P/ABV (x)	2.1	1.5	1.3	1.1	0.9			

Source: Company, Emkay Research

### Calibrated business growth hurts margins

After delivering healthy AUM growth for the last 8 quarters, Ujjivan SFB's AUM growth moderated to 19% YoY/1% QoQ in Q1FY25, and net advances grew 22% YoY/1% QoQ to Rs271bn due to lower disbursements, as it turned cautious in 1Q. This is primarily because of the watchful approach adopted by the SFB toward acquiring NTC customers across all segments amid rising asset-quality concerns. Deposit growth, too, was moderate, at 22% YoY/3% QoQ, with CASA ratio slipping to 25.6% (down by 85bps QoQ). This, coupled with contraction in LDR, led to a 10bps QoQ decline in NIMs to 9.3%. Going forward, the bank expects credit growth at ~20%, given concerted efforts to diversify its portfolio and increase share of its secured book (AHS, M-LAP, VF, gold loan, and new MSE book) to ~40% of gross advances by FY26 from current levels of 31.3%. It also expects NIMs to moderate to 9% in FY25, as cost pressure remains elevated.

### Asset quality slips owing to elections

Fresh slippages were elevated at Rs1.9bn/2.8% of loans, on seasonality/election-related disruption in collections (collection efficiency down to 98% vs 99% in Q4FY24) in the MFI space. This led to 28bps QoQ increment in GNPA ratio to 2.5%. Ujjivan carries a relatively strong PCR of 84% on its back-book, while also carrying floating provisions to the extent of Rs2.5bn/0.8% of loans. We believe the bank could further shore-up provision buffers to avoid meaningful P&L disruption as asset quality deteriorates and this, hence, could lead to elevated credit cost of  $\sim 1.7\%$  in FY25E, increasing gradually thereafter.

### We retain BUY on Ujjivan SFB, but cut our TP to Rs60/sh

We cut our FY25E-27E earnings estimate by 3-4%, factoring in the slightly slower growth and higher credit cost, but expect the bank to still deliver superior RoA/RoE at 2.5-2.9%/~20-21% over FY25E-27E. We retain BUY on the stock, though we trim our TP to Rs60/share (Rs65 earlier) mainly due to a cut in the P/ABV multiple to 1.4x which echoes the industry-wide growth/asset-quality stress and the cut in its earnings estimates. Ujjivan has taken Board approval to apply for a 'Universal Banking' license in FY25 which we believe is a long-term stock catalyst. **Key risks**: Macro/micro disruption leading to slower growth; higher NPAs with seasoning of the MFI/SME book; KMP attrition.

Target Price – 12M	Jun-25
Change in TP (%)	(7.7)
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	36.6
CMP (25-Jul-24) (Rs)	43.9

Stock Data	Ticker
52-week High (Rs)	63
52-week Low (Rs)	40
Shares outstanding (mn)	1,933.8
Market-cap (Rs bn)	85
Market-cap (US\$ mn)	1,014
Net-debt, FY25E (Rs mn)	NA
ADTV-3M (mn shares)	17
ADTV-3M (Rs mn)	810.5
ADTV-3M (US\$ mn)	9.7
Free float (%)	26.0
Nifty-50	24,406
INR/US\$	83.7
Shareholding, Jun-24	
Promoters (%)	-
FPIs/MFs (%)	24.7/7.3

Price Performance							
(%)	1M	3M	12M				
Absolute	(2.9)	(17.4)	(0.2)				
Rel. to Nifty	(5.6)	(23.6)	(19.5)				



### Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480

### Kunaal N


kunaal.n@emkayglobal.com +91 22 6612 1275

### Marazbaan Dastur

marazbaan.dastur@emkayglobal.com +91 22 6612 1281


## **Story in Charts**

Exhibit 1: Growth slows a bit, as the bank turns cautious on MFI




Source: Company, Emkay Research

Exhibit 3: CASA ratio remains range bound




Source: Company, Emkay Research

Exhibit 5: Fresh slippages were higher, leading to slight increase in GNPA ratio




Source: Company, Emkay Research

Exhibit 7: PAR book inching-up, but well under control




Source: Company, Emkay Research

Exhibit 2: MFI share remains high at 69%, but set to moderate




Source: Company, Emkay Research

Exhibit 4: NIM slips slightly, QoQ




Source: Company, Emkay Research

Exhibit 6: Overall collection efficiency took a small tumble 1Q




Source: Company, Emkay Research

Exhibit 8: RoA slips a tad in 1Q due to slower growth, lower other income, and elevated LLP



#### Exhibit 9: Return ratios expected to remain healthy, aided by reducing opex



Source: Company, Emkay Research

Exhibit 10: The stock currently trades at 1.2x one-year forward P/ABV



Source: Bloomberg, Emkay Research

### Exhibit 11: Actuals vs. Estimates (Q1FY25)

(Rs mn) Actuals	Actuals	Estimates		Varia	tion	Comments
	Emkay	Consensus	Emkay	Consensus		
Net income	11,386	11,745	11,756	-3%	-3%	Lower other income led to a slight miss
PPOP	5,095	5,272	5,419	-3%	-6%	Lower net total income led to a miss on PPoP
PAT	3,011	3,121	2,932	-4%	3%	Lower PPOP partly offset by lower tax led to a miss

Source: Company, Emkay Research

**Exhibit 12: Quarterly Summary** 

(Rs mn)	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	YoY (%)	QoQ (%)	FY24A	FY25E	YoY (%)
Interest Earned	12,869	13,911	14,706	15,285	15,772	23	3	56,772	67,280	19
Interest Exp.	4,942	5,678	6,107	5,950	6,357	29	7	22,677	27,407	21
Net Interest Income	7,927	8,233	8,599	9,335	9,415	19	1	34,094	39,873	17
Global NIMs (reported)	9.2	8.8	8.8	9.4	9.3	10bps	-10bps	9.6	9.3	-28bps
Non-interest Income	1,772	1,886	1,848	2,361	1,971	11	-17	7,868	9,154	16
Operating Expenses	5,120	5,286	5,874	6,511	6,290	23	-3	22,791	26,816	18
Pre-Provisioning Profit	4,579	4,834	4,573	5,186	5,095	11	-2	19,171	22,210	16
Provision & Contingencies	261	469	629	790	1,099	321	39	2,149	5,123	138
PBT	4,318	4,364	3,944	4,396	3,997	-7	-9	17,022	17,088	0
Income Tax Expense (Gain)	1,077	1,087	943	1,099	986	-8	-10	4,207	4,306	2
Net Profit/(Loss)	3,241	3,277	3,001	3,296	3,011	-7	-9	12,815	12,781	0
Gross NPA (%)	2.6	2.4	2.2	2.2	2.5	-10bps	28bps	2.2	2.3	2bps
Net NPA (%)	0.1	0.1	0.2	0.3	0.4	35bps	13bps	0.3	0.4	13bps
Deposits (Rs bn)	266.6	291.4	296.7	314.6	325.1	22	3	314.6	385.8	22.6
Net Advances (Rs bn)	221.7	243.3	256.2	268.8	271.1	22	1	268.8	323.0	20.1

Source: Company, Emkay Research

**Exhibit 13: Revision in estimates** 

Y/E Mar (Rs mn)	FY25E			FY26E			FY27E		
	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
Net income	50,757	49,027	-3.4%	59,877	58,503	-2.3%	72,235	70,347	-2.6%
PPOP	23,294	22,210	-4.7%	27,365	27,242	-0.5%	33,906	33,750	-0.5%
PAT	13,253	12,781	-3.6%	14,734	14,222	-3.5%	16,724	16,683	-0.2%
EPS (Rs)	6.9	6.6	-3.6%	7.6	7.4	-3.5%	8.7	8.6	-0.2%
BV (Rs)	34.7	34.5	-0.6%	41.0	40.5	-1.2%	48.1	47.6	-1.1%

**Exhibit 14: Key Assumptions** 

	FY24A	FY25E	FY26E	FY27E
Loan Growth (%)	26.3	20.1	22.9	22.7
Deposit Growth (%)	23.2	22.6	25.2	25.4
NIM (%)	9.6	9.3	9.1	9.0
GNPA (%)	2.2	2.3	2.4	2.7
Credit Cost (%)	0.7	1.7	2.2	2.5

Source: Emkay Research

Exhibit 15: Key ratios and trends	,
-----------------------------------	---

	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25
Loans (Rs mn)	194,090	209,380	218,960	240,860	253,260	265,750	277,910	297,790	300,690
Growth YoY (%)	38.3	44.3	33.0	32.6	30.5	26.9	26.9	23.6	18.7
Growth QoQ (%)	6.9	7.9	4.6	10.0	5.1	4.9	4.6	7.2	1.0
Composition (%)									
- MFI	68.8	69.2	70.6	72.1	72.3	72.1	71.3	69.9	68.9
- SME (MSE)	9.1	8.9	8.0	6.6	6.0	5.4	5.0	4.7	4.7
- Retail (Housing)	15.0	14.7	14.4	14.1	14.5	15.2	15.9	16.5	17.3
- Others	7.2	7.2	7.1	7.2	7.2	7.3	7.8	8.8	9.1
Liability Profile (%)									
Deposit (Rs mn)	184,490	203,962	232,030	255,377	266,600	291,393	296,690	314,622	325,140
Growth YoY	34.9	44.8	49.1	39.6	44.5	42.9	27.9	23.2	22.0
Growth QoQ	0.9	10.6	13.8	10.1	4.4	9.3	1.8	6.0	3.3
CASA (Rs mn)	51,550	54,960	60,700	67,440	65,550	70,130	75,490	83,320	83,350
CASA ratio	28	27	26	26	25	24	25	26	26
Asset Quality									
Gross NPA (Rs mn)	11,467	9,289	7,376	6,306	5,965	5,860	5,707	6,125	6,972
Net NPA (Rs mn)	178	73	95	90	126	218	428	763	1,112
GNPA (%)	6.5	5.1	3.6	2.9	2.6	2.4	2.2	2.2	2.5
NNPA (%)	0.1	0.0	0.1	0.0	0.1	0.1	0.2	0.3	0.4
RSA (%)	4.0	2.7	1.5	1.1	0.8	0.6	0.5	0.4	0.0
Specific PCR (%)	98.4	99.2	98.7	98.6	97.9	96.3	92.0	87.5	84.0
Capital Adequacy (%)									
CRAR	20.0	26.7	26.0	25.8	26.7	25.2	24.4	24.7	24.9
Tier-I	18.7	23.4	22.8	22.7	23.6	22.5	22.0	22.6	23.0
ROE Decomposition - on total assets (%)									
NII	10.0	10.4	9.7	9.3	9.3	9.0	8.8	9.3	9.1
Other Income	2.1	2.3	1.9	2.2	2.1	2.1	1.9	2.4	1.9
Net Income	12.1	12.7	11.7	11.5	11.4	11.0	10.7	11.7	11.0
Opex	7.1	6.7	6.2	6.4	6.0	5.8	6.0	6.5	6.1
PPOP	5.0	6.0	5.4	5.1	5.4	5.3	4.7	5.2	4.9
Provisions	0.5	(0.2)	(0.0)	(0.0)	0.3	0.5	0.6	0.8	1.1
PBT	4.5	6.2	5.4	5.2	5.1	4.8	4.0	4.4	3.9
Tax	1.1	1.6	1.3	1.3	1.3	1.2	1.0	1.1	1.0
ROA	3.4	4.6	4.1	3.9	3.8	3.6	3.1	3.3	2.9
Leverage (x)	8.2	7.5	7.3	7.7	7.8	7.9	7.9	7.5	7.1
ROE	27.9	34.7	29.9	29.9	29.6	28.2	24.4	24.6	20.9

FY26E

19.314

58.849

78,163

482,828

19,592

502,419

13,357

593.940

396.925

145,943

36,174

5,836

9,061

40.5

39.7

82.2

28.7

7.2

66.8

22.9

25.2

17.3

593,940

404.707

579,042

FY27E

19.314

72.635

91,949

605,581 18,612

624,193

13,746

729.888

487.220

181,305

44,942

6,834

9,587

47.6

46.6

80.5

30.6

7.0

66.8

22.7

25.4

17.6

729,888

497.789

713,468

### Ujjivan Small Finance Bank: Standalone Financials and Valuations

Profit & Loss					
	EVAA	EV24	EVALE	EVACE	EVAZE
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Interest Income	41,650	56,772	67,280	80,227	96,888
Interest Expense	14,671	22,677	27,407	32,446	38,927
Net interest income	26,979	34,094	39,873	47,781	57,961
NII growth (%)	52.1	26.4	16.9	19.8	21.3
Other income	5,892	7,868	9,154	10,722	12,386
Total Income	32,871	41,962	49,027	58,503	70,347
Operating expenses	18,021	22,791	26,816	31,262	36,596
PPOP	14,850	19,171	22,210	27,242	33,750
PPOP growth (%)	133.1	29.1	15.9	22.7	23.9
Core PPOP	14,833	18,931	21,835	26,773	33,234
Provisions & contingencies	178	2,149	5,123	8,229	11,447
PBT	14,672	17,022	17,088	19,013	22,303
Extraordinary items	0	0	0	0	0
Tax expense	3,673	4,207	4,306	4,791	5,620
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	10,999	12,815	12,781	14,222	16,683
PAT growth (%)	(365.3)	16.5	(0.3)	11.3	17.3
Adjusted PAT	10,999	12,815	12,781	14,222	16,683
Diluted EPS (Rs)	6.0	6.6	6.6	7.4	8.6
Diluted EPS growth (%)	(348.9)	10.4	0.3	11.3	17.3
DPS (Rs)	0.8	0.4	1.2	1.4	1.5
Dividend payout (%)	13.3	5.3	18.1	19.0	17.4
Effective tax rate (%)	25.0	24.7	25.2	25.2	25.2
Net interest margins (%)	9.8	9.6	9.3	9.1	9.0
Cost-income ratio (%)	54.8	54.3	54.7	53.4	52.0
Shares outstanding (mn)	1,954.7	1,931.4	1,931.4	1,931.4	1,931.4

Source: Company, Emkay Research

Balance Sheet Y/E Mar (Rs mn)

Reserves & surplus

Interest bearing liab.

Other liabilities & prov.

Total liabilities & equity

Cash, other balances

Interest earning assets

Share capital

Net worth

Borrowings

Net advances

Investments

Other assets

Total assets

Adj. BVPS (INR)

Gross advances

CASA ratio (%)

Credit to deposit (%)

Cost of deposits (%)

Loans-to-Assets (%) Net advances growth (%)

Deposit growth (%)

Book value growth (%)

BVPS (Rs)

Deposits

FY23

19.547

20,544

40,091

255,377

28,415

9,286

333.169

212.897

85,103

24,836

2,829

7.504

20.5

20.5

83.4

26.4

6.0

63.9

30.6

39.6

39.5

333,169

219.112

322,836

283,791

FY24

19,314

36.820

56,135

314,622

21.708

336,330

11,758

104,222

268.829

97,660

25,368

4,267

8.098

29.1

28.8

85.4

26.7

7.1

66.5

26.3

23.2

41.7

404,222

274.192

391,857

FY25E

19,314

47.331

66,645

385,778

20,623

406,401

10,777

483.823

322,952

118,057

29,261

470,270

483,823

329.030

8.565

34.5

34.0

83.7

26.9

7.5

66.8

20.1

22.6

18.7

Source.	Company,	LIIIKay	Research	

Asset quality and othe	r metrics				
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Asset quality					
Gross NPLs	6,306.2	6,125.3	7,411.8	9,726.7	13,211.3
Net NPLs	90.4	762.9	1,334.1	1,945.3	2,642.3
GNPA ratio (%)	2.9	2.2	2.3	2.4	2.7
NNPA ratio (%)	0.0	0.3	0.4	0.5	0.5
Provision coverage (%)	98.6	87.5	82.0	80.0	80.0
Gross slippages	3,350.0	4,797.8	7,567.7	10,522.4	13,938.1
Gross slippage ratio (%)	1.5	1.7	2.3	2.6	2.8
LLP ratio (%)	0.1	0.9	1.7	2.2	2.5
NNPA to networth (%)	0.2	1.3	2.0	2.4	2.8
Capital adequacy					
Total CAR (%)	23.5	29.0	26.9	25.8	24.8
Tier-1 (%)	22.5	28.1	26.2	25.2	24.3
CET-1 (%)	22.5	28.1	26.2	25.2	24.3
RWA-to-Total Assets (%)	49.1	46.6	50.0	50.0	50.0
Miscellaneous					
Total income growth (%)	49.8	36.0	18.2	19.0	20.1
Opex growth (%)	20.4	26.5	17.7	16.6	17.1
Core PPOP growth (%)	139.5	27.6	15.3	22.6	24.1
PPOP margin (%)	31.2	29.7	29.1	30.0	30.9
PAT/PPOP (%)	74.1	66.8	57.5	52.2	49.4
LLP-to-Core PPOP (%)	1.2	11.4	23.5	30.7	34.4
Yield on advances (%)	19.8	20.7	20.1	19.8	19.5
Cost of funds (%)	6.0	7.3	7.4	7.1	6.9

Source:	Company,	Emkay	Research


Valuations and key	Ratios				
Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E
P/E (x)	7.4	6.7	6.6	6.0	5.1
P/B (x)	2.1	1.5	1.3	1.1	0.9
P/ABV (x)	2.1	1.5	1.3	1.1	0.9
P/PPOP (x)	5.8	4.4	3.8	3.1	2.5
Dividend yield (%)	1.8	0.8	2.7	3.2	3.4
DuPont-RoE split (%)					
NII/avg assets	9.5	9.2	9.0	8.9	8.8
Other income	2.1	2.1	2.1	2.0	1.9
Fee income	2.1	2.1	2.0	1.9	1.8
Opex	6.3	6.2	6.0	5.8	5.5
PPOP	5.2	5.2	5.0	5.1	5.1
Core PPOP	5.2	5.1	4.9	5.0	5.0
Provisions	0.1	0.6	1.2	1.5	1.7
Tax expense	1.3	1.1	1.0	0.9	0.8
RoA (%)	3.9	3.5	2.9	2.6	2.5
Leverage ratio (x)	8.6	7.7	7.2	7.4	7.8
RoE (%)	33.3	26.6	20.8	19.6	19.6
Quarterly data					
Rs mn, Y/E Mar	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25
NII	7,927	8,233	8,599	9,335	9,415
NIM(%)	11.2	11.2	11.2	11.2	11.2
PPOP	4,579	4,834	4,573	5,186	5,095
PAT	3,241	3,277	3,001	3,296	3,011
EPS (Rs)	1.66	1.68	1.53	1.69	1.54

### **RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
23-Jun-24	48	65	Buy	Anand Dama
21-May-24	53	65	Buy	Anand Dama
25-Jan-24	55	65	Add	Anand Dama
30-Nov-23	57	65	Add	Anand Dama
27-Oct-23	53	65	Buy	Anand Dama
02-Oct-23	54	58	Buy	Anand Dama
27-Jul-23	44	58	Buy	Anand Dama
01-Jul-23	38	50	Buy	Anand Dama
12-Jun-23	37	50	Buy	Anand Dama
12-May-23	31	38	Buy	Anand Dama
09-Mar-23	27	33	Hold	Anand Dama
03-Feb-23	30	33	Hold	Anand Dama
08-Nov-22	28	30	Hold	Anand Dama
27-Jul-22	20	18	Hold	Anand Dama
15-May-22	18	14	Sell	Anand Dama
09-Feb-22	19	13	Sell	Anand Dama
11-Nov-21	21	15	Sell	Anand Dama
20-Aug-21	20	17	Sell	Anand Dama
08-Aug-21	27	23	Sell	Anand Dama

Source: Company, Emkay Research

### **RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information. it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

#### RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests 2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

1 An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of July 26, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- 3 EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of July 26, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the July 26, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

### **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

### **Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

#### OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.